14678-99-0

Basic information

• Product Name: 2-P-TOLYL-2H-PYRAZOL-3-YLAMINE
• Synonyms: 2-P-TOLYL-2H-PYRAZOL-3-YLAMINE;2-(4-Methylphenyl)-2H-pyrazol-3-ylamine
• CAS NO: 14678-99-0
• Molecular Formula: C₁₀H₁₁N₃
• Molecular Weight: 173.21
• Mol File: 14678-99-0.mol
• Article Data: 4

Chemical Properties

• Appearance: /
• Storage Temp.: 2-8°C(protect from light)
• CAS DataBase Reference: 2-P-TOLYL-2H-PYRAZOL-3-YLAMINE(CAS DataBase Reference)
• NIST Chemistry Reference: 2-P-TOLYL-2H-PYRAZOL-3-YLAMINE(14678-99-0)
• EPA Substance Registry System: 2-P-TOLYL-2H-PYRAZOL-3-YLAMINE(14678-99-0)

Safety Data

• Hazardous Substances Data: 14678-99-0(Hazardous Substances Data)

Upstream product

• 1820-80-0 3-aminopyrazole 
• 624-31-7 4-tolyl iodide 
• 539-44-6 N-4-methylphenylhydrazine 
• 15001-11-3 ethyl 5-amino-1-(p-tolyl)-1H-pyrazole-4-carboxylate 

Downstream Products

• 15001-22-6 4-acetylamino-N-(2-p-tolyl-2H-pyrazol-3-yl)-benzenesulfonamide 
• 1443247-33-3 1-[(1S,4R)-4-(3-isopropyl-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy)-1,2,3,4-tetrahydro-naphthalen-1-yl]-3-(2-p-tolyl-2H-pyrazol-3-yl)-urea 
• 1443248-32-5 (2-p-tolyl-2H-pyrazol-3-yl)-carbamic acid 2,2,2-trichloro-ethyl ester 
• 1003597-19-0 7-chloro-4-[(3-methyl-1-methylphenyl-1H-pyrazol-5-yl)amino]quinoline 

Relevant articles and documents

The optimization and characterization of functionalized sulfonamides derived from sulfaphenazole against Mycobacterium tuberculosis with reduced CYP 2C9 inhibition

In this study, a series of sulfonamide compounds was designed and synthesized through the systematic optimization of the antibacterial agent sulfaphenazole for the treatment of Mycobacterium tuberculosis (M. tuberculosis). Preliminary results indicate that the 4-aminobenzenesulfonamide moiety plays a key role in maintaining antimycobacterial activity. Compounds 10c, 10d, 10f and 10i through the optimization on phenyl ring at the R2 site on the pyrazole displayed promising antimycobacterial activity paired with low cytotoxicity. In particular, compound 10d displayed good activity (MIC = 5.69 μg/mL) with low inhibition of CYP 2C9 (IC50 > 10 μM), consequently low potential risk of drug-drug interaction. These promising results provide new insight into the combination regimen using sulfonamide as one component for the treatment of M. tuberculosis.

TETRAZOLE COMPOUNDS AS OREXIN RECEPTOR ANTAGONISTS

The invention relates to tetrazole compounds of formula (I) wherein X, Y, Z, R1, R2 and R3 are as described in the description; to pharmaceutically acceptable salts thereof, and to the use of such compounds use as medicaments, especially as orexin receptor antagonists.